Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases
The invention provides methods and compositions for the treatment and prevention of a transmittable disease in a subject, such as avians and mammals. The methods and compositions of the invention specifically make use of avian antibodies to the disease to be treated or prevented. Administration of such avian antibodies to a subject has been shown effective for reducing mortality in a population of subjects that are infected, or become infected, with the disease. The invention also provides kits useful for detecting the presence of transmittable diseases in subjects.
1. A method of treating a mammal comprising administering to the mammal an amount of a composition comprising polyclonal goose antibodies against a transmittable viral disease, wherein the goose antibodies are not administered to the mammal prior to administering the composition.
2. A method of treating a mammal infected with a transmittable viral disease, the method comprising administering to the mammal after infection an amount of a serum comprising polyclonal goose antibodies against the transmittable viral disease, wherein the serum exhibits a neutralization titer of at least about 1:500 when evaluated according to a plaque reduction test, wherein the transmittable virus is West Nile Virus and wherein the goose antibodies are not administered to the mammal prior to administering the serum.
3. A method of treating a mammal comprising administering to the mammal an amount of a serum comprising polyclonal goose antibodies against a transmittable viral disease, wherein the antibodies are from a goose that has been infected by a naturally occurring strain of the transmittable viral disease such that the serum exhibits a neutralization titer of at least about 1:500 when evaluated according to a plaque reduction test, wherein the transmittable virus is West Nile Virus and wherein the goose antibodies are not administered to the mammal prior to administering the serum.
4. A method of treating a mammal comprising administering to the mammal an amount of a serum comprising polyclonal goose antibodies against a transmittable viral disease, wherein the serum exhibits a neutralization titer of at least about 1:2000 when evaluated according to a plaque reduction test, wherein the transmittable virus is West Nile Virus and wherein the goose antibodies are not administered to the mammal prior to administering the serum.
5. The method of claim 1 , wherein the mammal is selected from the group consisting of goats, horses, rabbits, rats, mice, pigs, and humans.
6. The method of claim 1 , wherein said treating comprises administering the composition to a mammal that is infected with the transmittable viral disease.
7. The method of claim 1 , wherein the antibodies are from a goose that has been infected by a naturally occurring strain of the transmittable viral disease.
8. The method of claim 1 , wherein said administering comprises a route of administration selected from the group consisting of injection, inhalation, oral administration, and combinations thereof.
9. The method of claim 1 , wherein the transmittable viral disease is selected from the group consisting of West Nile Virus, Hepatitis B, influenza viruses, and avian influenza viruses.
10. The method of claim 1 , wherein the transmittable viral disease is Hepatitis B.
11. The method of claim 1 , wherein the transmittable viral disease is West Nile Virus.
12. The method of claim 1 , wherein the transmittable viral disease is an influenza virus.
13. The method of claim 1 , wherein the transmittable viral disease is an avian influenza virus.
14. The method of claim 9 , wherein said treating comprises preventing infection in the mammal by the transmittable viral disease.
15. The method of claim 9 , wherein said treating comprises preventing or limiting one or more symptoms associated with infection by the transmittable viral disease.
16. The method of claim 11 , wherein the polyclonal goose antibodies are from a serum that exhibits a neutralization titer of at least about 1:200 when evaluated according to a plaque reduction test.
17. The method of claim 16 , wherein the polyclonal goose antibodies are from a serum that exhibits a neutralization titer of at least about 1:500 when evaluated according to a plaque reduction test.
18. The method of claim 16 , wherein the polyclonal goose antibodies are from a serum that exhibits a neutralization titer of at least about 1:1000 when evaluated according to a plaque reduction test.